- Home
- NOM vs RLMD Comparison
NOM vs RLMD Comparison
Compare NOM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- RLMD
- Stock Information
- Founded
- NOM 1993
- RLMD 2004
- Country
- NOM United States
- RLMD United States
- Employees
- NOM N/A
- RLMD N/A
- Industry
- NOM Investment Managers
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- RLMD Health Care
- Exchange
- NOM Nasdaq
- RLMD Nasdaq
- Market Cap
- NOM 25.2M
- RLMD 20.3M
- IPO Year
- NOM N/A
- RLMD N/A
- Fundamental
- Price
- NOM $10.95
- RLMD $0.65
- Analyst Decision
- NOM
- RLMD Buy
- Analyst Count
- NOM 0
- RLMD 3
- Target Price
- NOM N/A
- RLMD $5.00
- AVG Volume (30 Days)
- NOM 6.9K
- RLMD 230.3K
- Earning Date
- NOM 01-01-0001
- RLMD 08-06-2025
- Dividend Yield
- NOM 3.39%
- RLMD N/A
- EPS Growth
- NOM N/A
- RLMD N/A
- EPS
- NOM N/A
- RLMD N/A
- Revenue
- NOM N/A
- RLMD N/A
- Revenue This Year
- NOM N/A
- RLMD N/A
- Revenue Next Year
- NOM N/A
- RLMD N/A
- P/E Ratio
- NOM N/A
- RLMD N/A
- Revenue Growth
- NOM N/A
- RLMD N/A
- 52 Week Low
- NOM $8.52
- RLMD $0.24
- 52 Week High
- NOM $10.48
- RLMD $4.24
- Technical
- Relative Strength Index (RSI)
- NOM 57.48
- RLMD 51.63
- Support Level
- NOM $10.50
- RLMD $0.60
- Resistance Level
- NOM $11.11
- RLMD $0.74
- Average True Range (ATR)
- NOM 0.36
- RLMD 0.06
- MACD
- NOM 0.04
- RLMD 0.01
- Stochastic Oscillator
- NOM 56.66
- RLMD 47.88
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.